TA107 Breast cancer (early) - trastuzumab: information for the public

The summary of the key recommendations on on trastuzumab (herceptin) for the adjuvant treatment of early-stage HER2-positive breast cancer. It is written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets or any other suitable publication.